论文部分内容阅读
目的探讨α-1b干扰素与黄芩苷胶囊联合应用对慢性乙型肝炎(CHB)和早期肝硬化(LC)临床疗效。方法 71例慢性乙型肝炎和早期肝硬化患者随机分为对照组、治疗组。对照组33例(LC8例),α-1b干扰素(北京三元基因工程公司产品)300mU,肌肉注射1次/d,1个月后改3次/周,其间口服齐墩果酸片2片/次,3次/d。治疗组38例(LC10例)在对照组基础上加用黄芩苷胶囊(江西普众药业有限公司产品),口服,0.5g/次,3次/d,疗程均为6个月。治疗第1、3、6个月及治疗结束后6个月观察血常规、肝功能;乙型肝炎病毒HBV标志物及HBV-DNA。结果治疗前各组肝功能各指标间的差异无统计学意义,治疗停药后6个月治疗组的丙氨酸转氨酶复常率、HBV-DNA和乙型肝炎e抗原(HBeAg)阴转率均明显高于对照组(P<0.05)。结论干扰素α-1b与黄芩苷胶囊联合具有较好的降低转氨酶及抗病毒效果。
Objective To investigate the clinical effects of interferon α-1b combined with baicalin capsule on chronic hepatitis B (CHB) and early liver cirrhosis (LC). Methods 71 patients with chronic hepatitis B and early cirrhosis were randomly divided into control group and treatment group. Control group of 33 cases (LC8 cases), α-1b interferon (Beijing Sanyuan Gen Engineering Company) 300mU, intramuscular injection 1 / d, 1 month after the change 3 times / week, during oral administration of oleanolic acid tablets 2 Piece / time, 3 times / d. The treatment group 38 cases (LC10 cases) on the basis of the control group plus baicalin capsules (Jiangxi Public Pharmaceutical Co., Ltd. products), orally, 0.5g / time, 3 times / d, treatment were 6 months. The 1st, 3rd, 6th month of treatment and 6 months after the end of treatment were observed blood and liver function; Hepatitis B virus HBV markers and HBV-DNA. Results Before treatment, there was no significant difference between the indexes of liver function in each group. The normalization rate of alanine aminotransferase, the negative conversion rate of HBV-DNA and hepatitis B e antigen (HBeAg) in the treatment group at 6 months after treatment Were significantly higher than the control group (P <0.05). Conclusion Interferon α-1b combined with baicalin capsule has a better effect of reducing transaminase and anti-virus.